The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2
J Clin Invest 85, 397-407
Western Europe is moving through premium hydration, pharmacy-adjacent wellness, and direct-to-consumer nutrition brands
More people on tirzepatide also reached higher weightloss targets, such as 15% or more
UV & Sun Exposure Guidance Many users report introducing UV or sun exposure only after several days of consistent use, allowing time for melanocyte stimulation
The actions of DAT can be regulated by a wide range of factors and cellular events and can be summarized in three main categories: 1) ligand-binding (e.g